XBRU:HYL (Belgium)
Business Description
Hyloris Pharmaceuticals SA
Boulevard Gustave-Kleyer 17, Liege, BEL, 4000
Compare
Compare
Traded in other countries / regions
HYL.Belgium
•
52U.Germany
•
0AB6.UK
Description
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans three areas of focus IV Cardiovascular, Other Reformulations, and Established Market (high-barrier generics). It has two early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic IV, a non-opioid analgesic product for the treatment of pain. It has 12 product candidates in various stages of development.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 4.11 | |||||
| Equity-to-Asset | 0.76 | |||||
| Debt-to-Equity | 0.26 | |||||
| Debt-to-EBITDA | -1.16 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 14.3 | |||||
| Beneish M-Score | 14.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 210.7 | |||||
| 3-Year EBITDA Growth Rate | -19.7 | |||||
| 3-Year EPS without NRI Growth Rate | -22.3 | |||||
| 3-Year FCF Growth Rate | -27.7 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 52.08 | |||||
| 9-Day RSI | 48.63 | |||||
| 14-Day RSI | 47.56 | |||||
| 6-1 Month Momentum % | -13.85 | |||||
| 12-1 Month Momentum % | -5.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.6 | |||||
| Quick Ratio | 3.6 | |||||
| Cash Ratio | 3.37 | |||||
| Days Sales Outstanding | 112.63 | |||||
| Days Payable | 5814.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 96.54 | |||||
| Operating Margin % | -334.24 | |||||
| Net Margin % | -374 | |||||
| ROE % | -21.96 | |||||
| ROA % | -17.67 | |||||
| ROIC % | -93.53 | |||||
| ROC (Joel Greenblatt) % | -1536.68 | |||||
| ROCE % | -18.19 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 117.48 | |||||
| PB Ratio | 8.14 | |||||
| Price-to-Tangible-Book | 8.68 | |||||
| EV-to-EBIT | -32.93 | |||||
| EV-to-EBITDA | -33.36 | |||||
| EV-to-Revenue | 114.07 | |||||
| EV-to-FCF | -28.73 | |||||
| Price-to-Net-Current-Asset-Value | 10.13 | |||||
| Price-to-Net-Cash | 11.1 | |||||
| Earnings Yield (Greenblatt) % | -3.04 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3.096 | ||
| EPS (TTM) (€) | -0.45 | ||
| Beta | 0 | ||
| Volatility % | 28.47 | ||
| 14-Day RSI | 47.56 | ||
| 14-Day ATR (€) | 0.495561 | ||
| 20-Day SMA (€) | 14.23 | ||
| 12-1 Month Momentum % | -5.02 | ||
| 52-Week Range (€) | 12.7 - 19.1 | ||
| Shares Outstanding (Mil) | 28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hyloris Pharmaceuticals SA Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||